Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation

被引:29
|
作者
Rayes, N
Seehofer, D
Hopf, U
Neuhaus, R
Naumann, U
Bechstein, WO
Neuhaus, P
机构
[1] Humboldt Univ, Dept Surg, D-13355 Berlin, Germany
[2] Humboldt Univ, Dept Internal Med, Charite Campus Virchow Clin, D-13355 Berlin, Germany
关键词
D O I
10.1097/00007890-200101150-00016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Preliminary results of short-term famciclovir and lamivudine therapy in patients with hepatitis B virus (HBV) infection after liver transplantation revealed promising results. In a retrospective study the efficacy of long-term treatment with these substances was compared. Methods. A total of 53 HBV-infected adults (48 reinfections and 7 de novo infections) received antiviral treatment. A total of 32 of these patients were treated with famciclovir 3x500 mg, 20 of them were later switched to lamivudine, Fourteen patients received lamivudine, 150 mg/day orally, as first line therapy and 7 patients after failure of famciclovir-prophylaxis. Follow-up time was 8 to 62 months (mean 35 months). Response to therapy (HBV-DNA negative) was compared using Kaplan-Meier estimates. Potential influence factors (HBV-DNA and HBeAg pretransplant, HDV coinfection, pretreatment with famciclovir and immunosuppression) on treatment response were analyzed by log. Rank test (univariate); then a multivariate analysis (Cox multiple stepwise regression model) was applied. Results. A total of 19 and 76% of the patients treated with famciclovir and lamivudine resp. became HBV-DNA negative; 0 and 24% HBsAg negative. Lamivudine was also effective as second Line therapy. In a multivariate analysis of all 73 treatment courses, lamivudine treatment and KDV-coinfection were significant factors for better treatment response; regarding only the lamivudine group, negative HBeAg pretransplant was significant. Viral breakthrough after prolonged treatment occurred in 55% (lamivudine) to 80% (famciclovir) of treatment courses but was only accompanied by mild hepatitis. Conclusions. Lamivudine and famciclovir are potent drugs for the treatment of HBV-infection after liver transplantation. The antiviral capacity of lamivudine is superior even after pretreatment with famciclovir but after prolonged treatment viral breakthrough is often observed.
引用
收藏
页码:96 / 101
页数:6
相关论文
共 50 条
  • [1] Comparison of lamivudine and famciclovir for hepatitis B infection after liver transplantation
    Rayes, N
    Seehofer, D
    Müller, AR
    Bechstein, WO
    Berg, T
    Neuhaus, R
    Neuhaus, P
    [J]. TRANSPLANTATION, 1999, 67 (07) : S195 - S195
  • [2] Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation
    Ben-Ari, Z
    Mor, E
    Shapira, Z
    Tur-Kaspa, R
    [J]. JOURNAL OF HEPATOLOGY, 2001, 34 : 39 - 39
  • [3] Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation
    Ben-Ari, Z
    Mor, E
    Shapira, Z
    Tur-Kaspa, R
    [J]. LIVER TRANSPLANTATION, 2001, 7 (02) : 113 - 117
  • [4] Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation
    Woo, Hyun Young
    Choi, Jong Young
    Jang, Jeong Won
    You, Chan Ran
    Bae, Si Hyan
    Yoon, Seung Kew
    Yang, Jin Mo
    Choi, Sang Wook
    Han, Nam Ik
    Kim, Dong Goo
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (11) : 1891 - 1899
  • [5] Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation
    Rayes, N
    Seehofer, D
    Bechstein, WO
    Müller, AR
    Berg, T
    Neuhaus, R
    Neuhaus, P
    [J]. CLINICAL TRANSPLANTATION, 1999, 13 (06) : 447 - 452
  • [6] Long-term follow-up of lamivudine treatment for acute hepatitis B after liver transplantation.
    Caraceni, P
    Grazi, GL
    Belli, L
    Milandri, GL
    Jovine, E
    Dal Monte, PR
    Ideo, G
    Forti, D
    Mazziotti, A
    Cavallari, A
    Andreone, P
    Bernardi, M
    [J]. HEPATOLOGY, 1998, 28 (04) : 345A - 345A
  • [7] Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: Long-term results
    Dumortier, J
    Chevallier, P
    Scoazec, JY
    Berger, F
    Boillot, O
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (08) : 999 - 1002
  • [8] Substitution of lamivudine for long-term HBIG after liver transplantation for hepatitis B related liver disease.
    Dobson, SF
    Balan, V
    Shakil, O
    Bonham, A
    Rakela, J
    Fung, JJ
    [J]. HEPATOLOGY, 1998, 28 (04) : 262A - 262A
  • [9] LONG-TERM OUTCOME OF LAMIVUDINE MONO-PROPHYLAXIS AFTER LIVER TRANSPLANTATION IN HEPATITIS B PATIENTS
    Fung, James
    Chan, See-Ching
    Yuen, Man-Fung
    Lai, Ching-Lung
    Chok, Kenneth Siu Ho
    Sharr, William
    Dai, Wing-chiu
    Fan, Sheung Tat
    Lo, Chung-Mau
    [J]. HEPATOLOGY, 2011, 54 : 450A - 450A
  • [10] Limited lamivudine and long-term hepatitis B immunoglobulin immunoprophylaxis for prevention of hepatitis B recurrence after liver transplantation.
    Starkel, P
    Cicarelli, O
    Lerut, J
    Goubau, P
    Rahier, J
    Horsmans, Y
    [J]. TRANSPLANTATION, 2002, 74 (03) : 408 - 410